2015 ESC/ERS Guidelines for the diagnosis and treatment of ...

ESC/ERS GUIDELINES PULMONARY HYPERTENSION

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)

Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)

Nazzareno Gali?1 (ESC Chairperson), Marc Humbert2 (ERS Chairperson), Jean-Luc Vachiery3, Simon Gibbs1, Irene Lang1, Adam Torbicki1, G?rald Simonneau2, Andrew Peacock2, Anton Vonk Noordegraaf2, Maurice Beghetti4, Ardeschir Ghofrani2, Miguel Angel Gomez Sanchez1, Georg Hansmann4, Walter Klepetko3, Patrizio Lancellotti1, Marco Matucci5, Theresa McDonagh1, Luc A. Pierard1, Pedro T. Trindade1, Maurizio Zompatori6 and Marius Hoeper2

Affiliations: 1Representing the European Society of Cardiology. 2Representing the European Respiratory Society. 3Representing the International Society for Heart and Lung Transplantation. 4Representing the Association for European Paediatric and Congenital Cardiology. 5Representing the European League Against Rheumatism. 6Representing the European Society of Radiology. A full list of collaborators and document reviewers can be found in the Appendix.

Correspondence: Nazzareno Gali?, Dept of Experimental, Diagnostic and Specialty Medicine?DIMES, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. E-mail: nazzareno.galie@unibo.it Marc Humbert, Service de Pneumologie, H?pital Bic?tre, Universit? Paris-Sud, Assistance Publique H?pitaux de Paris, 78 rue du G?n?ral Leclerc, 94270 Le Kremlin-Bic?tre, France. E-mail: marc.humbert@aphp.fr

@ERSpublications 2015 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations focusing on clinical management

Editorial Comments in Eur Respir J 2015; 46: 879?882 [DOI: 10.1183/13993003.01177-2015].

This article has been revised according to the erratum published in the December 2015 issue of the European Respiratory Journal.

The content of these European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC/ERS Guidelines may be translated or reproduced in any form without written permission from the ESC and/or ERS. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal or from the European Respiratory Society, the publisher of European Respiratory Journal and the party authorized to handle such permissions on behalf of the ESC and ERS.

This article is being published concurrently in the European Heart Journal (10.1093/eurheartj/ehv317) and the European Respiratory Journal (10.1183/13993003.01032-2015). The articles are identical except for minor stylistic and spelling differences in keeping with each journal's style. Either citation can be used when citing this article.

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.

Published on behalf of the European Society of Cardiology and European Respiratory Society. All rights reserved. ? 2015 European Society of Cardiology & European Respiratory Society.

Eur Respir J 2015; 46: 903?975 | DOI: 10.1183/13993003.01032-2015

903

PULMONARY HYPERTENSION | N. GALI? ET AL.

Table of Contents

Abbreviation and acronyms 1. Preamble ...................................................................................................................... 905 2. Introduction .................................................................................................................. 907 3. Definitions and classifications .................................................................................... 907

3.1 Definitions ............................................................................................................ 907 3.2 Classifications...................................................................................................... 908 4. Epidemiology and genetics of pulmonary hypertension .......................................... 909 4.1 Epidemiology and risk factors............................................................................ 909 4.2 Genetics................................................................................................................ 911 5. Pulmonary hypertension diagnosis ............................................................................ 911 5.1 Diagnosis.............................................................................................................. 911

5.1.1 Clinical presentation .............................................................................. 913 5.1.2 Electrocardiogram .................................................................................. 913 5.1.3 Chest radiograph .................................................................................... 913 5.1.4 Pulmonary function tests and arterial blood gases ............................ 913 5.1.5 Echocardiography .................................................................................... 914 5.1.6 Ventilation/perfusion lung scan.............................................................. 915 5.1.7 High-resolution computed tomography, contrast enhanced

computed tomography, and pulmonary angiography .......................... 916 5.1.8 Cardiac magnetic resonance imaging .................................................. 916 5.1.9 Blood tests and immunology .................................................................. 917 5.1.10 Abdominal ultrasound scan.................................................................. 917 5.1.11 Right heart catheterization and vasoreactivity .................................... 917 5.1.12 Genetic testing ...................................................................................... 918 5.2 Diagnostic algorithm .......................................................................................... 919 6. Pulmonary arterial hypertension (group 1) .............................................................. 920 6.1 Clinical characteristics........................................................................................ 920 6.2 Evaluation of severity .......................................................................................... 920 6.2.1 Clinical parameters, imaging and haemodynamics ............................ 920 6.2.2 Exercise capacity .................................................................................... 922 6.2.3 Biochemical markers .............................................................................. 922 6.2.4 Comprehensive prognostic evaluation and risk

assessment .............................................................................................. 922 6.2.5 Definition of patient status...................................................................... 923 6.2.6 Treatment goals and follow-up strategy................................................ 924 6.3 Therapy ................................................................................................................ 924 6.3.1 General measures .................................................................................. 925 6.3.1.1 Physical activity and supervised rehabilitation .................................. 925 6.3.1.2 Pregnancy, birth control, and post-menopausal

hormonal therapy ................................................................................ 926 6.3.1.3 Elective surgery .................................................................................... 926 6.3.1.4 Infection prevention .............................................................................. 926 6.3.1.5 Psychosocial support .......................................................................... 926 6.3.1.6 Adherence to treatments .................................................................... 927 6.3.1.7 Travel .................................................................................................... 927 6.3.1.8 Genetic counselling .............................................................................. 927 6.3.2 Supportive therapy .................................................................................. 927 6.3.2.1 Oral anticoagulants .............................................................................. 928 6.3.2.2 Diuretics ................................................................................................ 928 6.3.2.3 Oxygen .................................................................................................. 928 6.3.2.4 Digoxin and other cardiovascular drugs ............................................ 928 6.3.2.5 Anaemia and iron status ...................................................................... 928 6.3.3 Specific drug therapy .............................................................................. 928 6.3.3.1 Calcium channel blockers .................................................................. 928 6.3.3.2 Endothelin receptor antagonists ........................................................ 929 6.3.3.3 Phosphodiesterase type 5 inhibitors and guanylate cyclase

stimulators ............................................................................................ 930

6.3.3.4 Prostacyclin analogues and prostacyclin receptor agonists ............ 931 6.3.3.5 Experimental compounds and strategies .......................................... 932 6.3.4 Combination therapy .............................................................................. 933 6.3.5 Drug interactions .................................................................................... 936 6.3.6 Balloon atrial septostomy ...................................................................... 936 6.3.7 Advanced right ventricular failure.......................................................... 936 6.3.7.1 Intensive care unit management ........................................................ 936 6.3.7.2 Right ventricle assistance.................................................................... 937 6.3.8 Transplantation ........................................................................................ 937 6.3.9 Treatment algorithm .............................................................................. 938 6.3.10 Diagnosis and treatment of pulmonary arterial

hypertension complications .................................................................. 939 6.3.10.1 Arrhythmias ........................................................................................ 939 6.3.10.2 Haemoptysis........................................................................................ 940 6.3.10.3 Mechanical complications.................................................................. 940 6.3.11 End of life care and ethical issues ...................................................... 940 7. Specific pulmonary (arterial) hypertension subsets ................................................ 940 7.1 Paediatric pulmonary arterial hypertension .................................................... 940 7.1.1 Diagnosis.................................................................................................. 941 7.1.2 Therapy .................................................................................................... 941 7.2 Pulmonary arterial hypertension associated with adult congenital heart disease ...................................................................................... 942 7.2.1 Diagnosis.................................................................................................. 942 7.2.2 Therapy .................................................................................................... 942 7.3 Pulmonary arterial hypertension associated with connective tissue disease...................................................................................... 944 7.3.1 Diagnosis.................................................................................................. 945 7.3.2 Therapy .................................................................................................... 945 7.4 Pulmonary arterial hypertension associated with portal hypertension ............ 945 7.4.1 Diagnosis.................................................................................................. 945 7.4.2 Therapy .................................................................................................... 946 7.5 Pulmonary arterial hypertension associated with human immunodeficiency virus infection ........................................................................ 947 7.5.1 Diagnosis.................................................................................................. 947 7.5.2 Therapy .................................................................................................... 948 7.6 Pulmonary veno-occlusive disease and pulmonary capillary haemangiomatosis ................................................................................ 948 7.6.1 Diagnosis.................................................................................................. 949 7.6.2 Therapy .................................................................................................... 949 8. Pulmonary hypertension due to left heart disease (group 2) .................................... 950 8.1 Diagnosis.............................................................................................................. 951 8.2 Therapy ................................................................................................................ 952 9. Pulmonary hypertension due to lung diseases and/or hypoxia (group 3) ................ 952 9.1 Diagnosis.............................................................................................................. 953 9.2 Therapy ................................................................................................................ 954 10. Chronic thromboembolic pulmonary hypertension (group 4) ................................ 954 10.1 Diagnosis............................................................................................................ 954 10.2 Therapy .............................................................................................................. 956 10.2.1 Surgical .......................................................................................................... 956 10.2.2 Medical .......................................................................................................... 956 10.2.3 Interventional ................................................................................................ 957 11. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5) ...................................................................... 958 12. Definition of a pulmonary hypertension referral centre ........................................ 958 13. To do and not to do messages from the guidelines .............................................. 960 14. Appendix .................................................................................................................... 960 15. Web addenda .............................................................................................................. 962 16. References.................................................................................................................. 962

Disclaimer: The ESC/ERS Guidelines represent the views of the ESC and ERS and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC and ERS are not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC/ERS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/ERS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC/ERS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC/ERS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

904

DOI: 10.1183/13993003.01032-2015

PULMONARY HYPERTENSION | N. GALI? ET AL.

Abbreviations and acronyms

ALAT ASAT APAH BAS BMPR2 BNP BPA BREATHE

CAV1 CCB cGMP CHD CI CMR CO COPD Cpc-PH

CPET CPFE CT CTD CTPA CTEPH

DLCO

DPAH DPG EACVI ECG ECMO EIF2AK4 EMA ERA FC FDA HAART HIV HF-pEF

HPAH HRCT ICU INR IPAH Ipc-PH IPF

alanine aminotransferase aspartate aminotransferase associated pulmonary arterial hypertension balloon atrial septostomy bone morphogenetic protein receptor 2 brain natriuretic peptide balloon pulmonary angioplasty Bosentan Randomised trial of Endothelin Antagonist THErapy caveolin-1 calcium channel blocker cyclic guanosine monophosphate congenital heart disease cardiac index cardiac magnetic resonance cardiac output chronic obstructive pulmonary disease combined post-capillary and pre-capillary pulmonary hypertension cardiopulmonary exercise testing combined pulmonary fibrosis and emphysema computed tomography connective tissue disease computed tomography pulmonary angiogram chronic thromboembolic pulmonary hypertension diffusing capacity of the lung for carbon monoxide drug-induced pulmonary arterial hypertension diastolic pressure gradient (diastolic PAP - mean PAWP) European association of cardiovascular imaging electrocardiogram extracorporeal membrane oxygenation eukaryotic translation initiation factor 2 alpha kinase 4 European Medicines Agency endothelin receptor antagonist functional class US Food and Drug Administration highly active antiretroviral therapy human immunodeficiency virus heart failure with preserved left ventricular ejection fraction heritable pulmonary arterial hypertension high-resolution computed tomography intensive care unit international normalized ratio idiopathic pulmonary arterial hypertension isolated post-capillary pulmonary hypertension idiopathic pulmonary fibrosis

i.v. IVC LA LHD LV MR NYHA NO NT-proBNP PA PaCO2 PaO2 PAH PAP PAPm PAPs PAWP PASP PCH PDE-5i PE PEA PFTs PH PoPH PPHN

PVOD PVR RA RAP RCT RHC RV 6MWD/6MWT SCD sGC SSc SvO2 SVR TAPSE t.i.d. TGF- TPG

TRV VE/VCO2

V/Q WHO-FC WU

intravenous inferior vena cava left atrium/atrial left heart disease left ventricle/ventricular magnetic resonance New York Heart Association nitric oxide N-terminal pro-brain natriuretic peptide pulmonary artery arterial carbon dioxide pressure arterial oxygen pressure pulmonary arterial hypertension pulmonary arterial pressure mean pulmonary arterial pressure systolic pulmonary arterial pressure pulmonary artery wedge pressure pulmonary artery systolic pressure pulmonary capillary haemangiomatosis phosphodiesterase type 5 inhibitor pulmonary embolism pulmonary endarterectomy pulmonary function tests pulmonary hypertension porto-pulmonary hypertension persistent pulmonary hypertension of the newborn pulmonary veno-occlusive disease pulmonary vascular resistance right atrium right atrial pressure randomized controlled trial right heart catheterization right ventricle/ventricular 6-minute walking distance/6-minute walking test sickle cell disease soluble guanylate cyclase systemic sclerosis mixed venous oxygen saturation systemic vascular resistance tricuspid annular plane systolic excursion three times a day transforming growth factor transpulmonary pressure gradient (mean PAP - mean PAWP) tricuspid regurgitant velocity minute ventilation ? carbon dioxide production relationship ventilation/perfusion World Health Organization functional class Wood units

1. Preamble

Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, with the aim of assisting health professionals in selecting the best management strategies for an individual patient with a given condition, taking into account the impact on outcome, as well as the risk? benefit ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) and by the European Respiratory Society (ERS), as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website ( Guidelines-&-Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

Members of this Task Force were selected by the ESC and ERS to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive

DOI: 10.1183/13993003.01032-2015

905

PULMONARY HYPERTENSION | N. GALI? ET AL.

review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) policy and approved by the ERS. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk?benefit ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined in Tables 1 and 2.

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (). Any changes in declarations of interest that arise during the writing period must be notified to the ESC and ERS and updated. The Task Force received its entire financial support from the ESC and ERS without any involvement from the healthcare industry.

The ESC CPG supervises and coordinates the preparation of new Guidelines produced by task forces, expert groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts, and in this case by ERS-appointed experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task Force. The finalized document is approved by the CPG and by ERS for publication in the European Heart Journal and in the European Respiratory Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The task of developing ESC/ERS Guidelines covers not only integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. To implement the guidelines, condensed pocket guideline versions, summary slides, booklets with essential messages, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.) are produced. These versions are abridged and thus, if needed, one should always refer to the full text version, which is freely available on the ESC website. The National Societies of the ESC are encouraged to endorse, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them and implementing them into clinical practice.

TABLE 1 Classes of recommendations

Classes of recommendations Class I

Class II

Definition

Suggested wording to use

Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.

Is recommended/is indicated

Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.

Class IIa Class IIb Class III

Weight of evidence/opinion is in favour of usefulness/efficacy.

Should be considered

Usefulness/efficacy is less well established by May be considered evidence/opinion.

Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.

Is not recommended

906

DOI: 10.1183/13993003.01032-2015

PULMONARY HYPERTENSION | N. GALI? ET AL.

TABLE 2 Level of evidence

Level of

Data derived from multiple randomized clinical trials

evidence A or meta-analyses.

Level of

Data derived from a single randomized clinical trial or

evidence B large non-randomised studies.

Level of

Consensus of opinion of the experts and/or small

evidence C studies, retrospective studies, registries.

Health professionals are encouraged to take the ESC/ERS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC/ERS Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and the patient's caregiver where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

2. Introduction

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple clinical conditions and can complicate the majority of cardiovascular and respiratory diseases. The composition of the guidelines task force reflects the multidisciplinary nature of PH, including members of different medical societies, associations and working groups. The current document follows the two previous ESC and ERS Guidelines, published in 2004 and 2009, focusing on clinical management of PH. A systematic literature review was performed from MEDLINE? to identify new studies published since 2009 concerning the topic of PH. Task force members selected studies based on relevance and appropriateness. The main changes and adaptations as compared with the 2009 ESC and ERS PH guidelines are as follows:

? The table of contents structure has been simplified, with three initial general chapters including classifications, basic aspects and differential diagnosis, two chapters for pulmonary arterial hypertension (PAH) and one chapter each for PH due to left heart disease (LHD), lung disease and/or hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH) and unclear and/or multifactorial mechanisms.

? New wordings and parameters for the haemodynamic definition of post-capillary PH subgroups have been adopted. Pulmonary vascular resistance (PVR) has been included in the haemodynamic definition of PAH.

? An updated common clinical classification for adult and paediatric patients is reported. ? New advances in pathology, pathobiology, genetics, epidemiology and risk factors are reported. ? An updated diagnostic algorithm has been provided in an independent chapter and novel screening

strategies are proposed in the web addenda. ? The importance of expert referral centres in the management of PH patients has been highlighted in

both the diagnostic and treatment algorithms. ? New developments on PAH severity evaluation and on treatments and treatment goals are reported,

including combination therapy and two new recently approved drugs. The treatment algorithm has been updated accordingly. ? The chapters on PH due to LHD and lung diseases have been updated. The term `out of proportion PH' has been abandoned in both conditions. ? New diagnostic and treatment algorithms are reported in the CTEPH chapter, including general criteria for operability and balloon pulmonary angioplasty (BPA) and a newly approved drug. ? A short chapter on PH due to unclear and/or multifactorial mechanisms has been added.

3. Definitions and classifications

3.1 Definitions PH is defined as an increase in mean pulmonary arterial pressure (PAPm) 25 mmHg at rest as assessed by right heart catheterization (RHC) [1]. Available data have shown that the normal PAPm at rest is 14 ? 3 mmHg with an upper limit of normal of approximately 20 mmHg [1, 2]. The clinical significance of a PAPm between 21 and 24 mmHg is unclear. Patients presenting with a pulmonary artery pressure (PAP) in this range should be carefully followed when they are at risk for developing PAH [e.g. patients with connective tissue disease (CTD) or family members of patients with heritable PAH (HPAH)] [1].

DOI: 10.1183/13993003.01032-2015

907

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download